APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tumor Treatment Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Tumor Treatment Drug Market Analysis and Forecast 2026-2032

2 January 2026215 pages

Choose your research edition.

Industry ResearchTumor Treatment Drug Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Tumor Treatment Drug Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Tumor Treatment Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tumor Treatment Drug Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Tumor Treatment Drug Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Tumor Treatment Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Tumor Treatment Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Tumor Treatment Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Tumor Treatment Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Tumor Treatment Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Tumor Treatment Drug include Astellas, Biogen Idec, Bristol-Myers Squibb, Celgene, Gilead Sciences, Ipsen, Merck & Co., Otsuka and AstraZeneca, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Tumor Treatment Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Tumor Treatment Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Tumor Treatment Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Tumor Treatment Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Tumor Treatment Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Tumor Treatment Drug revenue, projected growth trends, production technology, application and end-user industry.

Tumor Treatment Drug Segment by Company

Astellas

Biogen Idec

Bristol-Myers Squibb

Celgene

Gilead Sciences

Ipsen

Merck & Co.

Otsuka

AstraZeneca

AbbVie

Amgen

Bayer

Pfizer

Eli Lilly

Roche

Merck KGaA

Novartis

Johnson & Johnson

Sanofi

Teva

Eisai

Takeda

Tumor Treatment Drug Segment by Type

Immunotherapy (Biologic Therapy)

Chemotherapy

Hormonal Therapy

Targeted Therapy

Others

Tumor Treatment Drug Segment by Application

Respiratory/Lung Cancer

Prostate Cancer

Breast Cancer

Gastrointestinal Cancer

Blood Cancer

Others

Tumor Treatment Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Treatment Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tumor Treatment Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Treatment Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Tumor Treatment Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Tumor Treatment Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Tumor Treatment Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Tumor Treatment Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Immunotherapy (Biologic Therapy) Major Player Table 3. Chemotherapy Major Player Table 4. Hormonal Therapy Major Player Table 5. Targeted Therapy Major Player Table 6. Others Major Player Table 7. Global Tumor Treatment Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Respiratory/Lung Cancer Major Player Table 9. Prostate Cancer Major Player Table 10. Breast Cancer Major Player Table 11. Gastrointestinal Cancer Major Player Table 12. Blood Cancer Major Player Table 13. Others Major Player Table 14. Tumor Treatment Drug Industry Trends Table 15. Tumor Treatment Drug Industry Drivers Table 16. Tumor Treatment Drug Industry Opportunities and Challenges Table 17. Tumor Treatment Drug Industry Restraints Table 18. Global Tumor Treatment Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 19. Global Tumor Treatment Drug Market Size by Region (2021-2026) & (US$ Million) Table 20. Global Tumor Treatment Drug Market Share by Region (2021-2026) Table 21. Global Tumor Treatment Drug Market Size by Region (2027-2032) & (US$ Million) Table 22. Global Tumor Treatment Drug Market Share by Region (2027-2032) Table 23. Global Tumor Treatment Drug Revenue by Players (US$ Million) & (2021-2026) Table 24. Global Tumor Treatment Drug Revenue Market Share by Players (2021-2026) Table 25. Global Tumor Treatment Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 26. Global Tumor Treatment Drug Key Players Headquarters & Area Served Table 27. Global Tumor Treatment Drug Players, Product Type & Application Table 28. Global Tumor Treatment Drug Players Establishment Date Table 29. Global Players Market Concentration Ratio (CR5 and HHI) Table 30. Global Tumor Treatment Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 31. Global Tumor Treatment Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Tumor Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 33. Global Tumor Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 34. Global Tumor Treatment Drug Revenue Market Share by Type (2021-2026) Table 35. Global Tumor Treatment Drug Revenue Market Share by Type (2027-2032) Table 36. Global Tumor Treatment Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Tumor Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 38. Global Tumor Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 39. Global Tumor Treatment Drug Revenue Market Share by Application (2021-2026) Table 40. Global Tumor Treatment Drug Revenue Market Share by Application (2027-2032) Table 41. Astellas Company Information Table 42. Astellas Business Overview Table 43. Astellas Tumor Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Astellas Tumor Treatment Drug Product Portfolio Table 45. Astellas Recent Development Table 46. Biogen Idec Company Information Table 47. Biogen Idec Business Overview Table 48. Biogen Idec Tumor Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Biogen Idec Tumor Treatment Drug Product Portfolio Table 50. Biogen Idec Recent Development Table 51. Bristol-Myers Squibb Company Information Table 52. Bristol-Myers Squibb Business Overview Table 53. Bristol-Myers Squibb Tumor Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Bristol-Myers Squibb Tumor Treatment Drug Product Portfolio Table 55. Bristol-Myers Squibb Recent Development Table 56. Celgene Company Information Table 57. Celgene Business Overview Table 58. Celgene Tumor Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Celgene Tumor Treatment Drug Product Portfolio Table 60. Celgene Recent Development Table 61. Gilead Sciences Company Information Table 62. Gilead Sciences Business Overview Table 63. Gilead Sciences Tumor Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Gilead Sciences Tumor Treatment Drug Product Portfolio Table 65. Gilead Sciences Recent Development Table 66. Ipsen Company Information Table 67. Ipsen Business Overview Table 68. Ipsen Tumor Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Ipsen Tumor Treatment Drug Product Portfolio Table 70. Ipsen Recent Development Table 71. Merck & Co. Company Information Table 72. Merck & Co. Business Overview Table 73. Merck & Co. Tumor Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Merck & Co. Tumor Treatment Drug Product Portfolio Table 75. Merck & Co. Recent Development Table 76. Otsuka Company Information Table 77. Otsuka Business Overview Table 78. Otsuka Tumor Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Otsuka Tumor Treatment Drug Product Portfolio Table 80. Otsuka Recent Development Table 81. AstraZeneca Company Information Table 82. AstraZeneca Business Overview Table 83. AstraZeneca Tumor Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. AstraZeneca Tumor Treatment Drug Product Portfolio Table 85. AstraZeneca Recent Development Table 86. AbbVie Company Information Table 87. AbbVie Business Overview Table 88. AbbVie Tumor Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. AbbVie Tumor Treatment Drug Product Portfolio Table 90. AbbVie Recent Development Table 91. Amgen Company Information Table 92. Amgen Business Overview Table 93. Amgen Tumor Treatment Drug Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Amgen Tumor Treatment Drug Product Portfolio Table 95. Amgen Recent Development Table 96. Bayer Company Information Table 97. Bayer Business Overview Table 98. Bayer Tumor Treatment Drug Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Bayer Tumor Treatment Drug Product Portfolio Table 100. Bayer Recent Development Table 101. Pfizer Company Information Table 102. Pfizer Business Overview Table 103. Pfizer Tumor Treatment Drug Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Pfizer Tumor Treatment Drug Product Portfolio Table 105. Pfizer Recent Development Table 106. Eli Lilly Company Information Table 107. Eli Lilly Business Overview Table 108. Eli Lilly Tumor Treatment Drug Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Eli Lilly Tumor Treatment Drug Product Portfolio Table 110. Eli Lilly Recent Development Table 111. Roche Company Information Table 112. Roche Business Overview Table 113. Roche Tumor Treatment Drug Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Roche Tumor Treatment Drug Product Portfolio Table 115. Roche Recent Development Table 116. Merck KGaA Company Information Table 117. Merck KGaA Business Overview Table 118. Merck KGaA Tumor Treatment Drug Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Merck KGaA Tumor Treatment Drug Product Portfolio Table 120. Merck KGaA Recent Development Table 121. Novartis Company Information Table 122. Novartis Business Overview Table 123. Novartis Tumor Treatment Drug Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Novartis Tumor Treatment Drug Product Portfolio Table 125. Novartis Recent Development Table 126. Johnson & Johnson Company Information Table 127. Johnson & Johnson Business Overview Table 128. Johnson & Johnson Tumor Treatment Drug Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Johnson & Johnson Tumor Treatment Drug Product Portfolio Table 130. Johnson & Johnson Recent Development Table 131. Sanofi Company Information Table 132. Sanofi Business Overview Table 133. Sanofi Tumor Treatment Drug Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Sanofi Tumor Treatment Drug Product Portfolio Table 135. Sanofi Recent Development Table 136. Teva Company Information Table 137. Teva Business Overview Table 138. Teva Tumor Treatment Drug Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Teva Tumor Treatment Drug Product Portfolio Table 140. Teva Recent Development Table 141. Eisai Company Information Table 142. Eisai Business Overview Table 143. Eisai Tumor Treatment Drug Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Eisai Tumor Treatment Drug Product Portfolio Table 145. Eisai Recent Development Table 146. Takeda Company Information Table 147. Takeda Business Overview Table 148. Takeda Tumor Treatment Drug Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Takeda Tumor Treatment Drug Product Portfolio Table 150. Takeda Recent Development Table 151. North America Tumor Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 152. North America Tumor Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 153. North America Tumor Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 154. North America Tumor Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 155. North America Tumor Treatment Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 156. North America Tumor Treatment Drug Revenue by Country (2021-2026) & (US$ Million) Table 157. North America Tumor Treatment Drug Revenue by Country (US$ Million) & (2027-2032) Table 158. Europe Tumor Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 159. Europe Tumor Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 160. Europe Tumor Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 161. Europe Tumor Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 162. Europe Tumor Treatment Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 163. Europe Tumor Treatment Drug Revenue by Country (2021-2026) & (US$ Million) Table 164. Europe Tumor Treatment Drug Revenue by Country (US$ Million) & (2027-2032) Table 165. China Tumor Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 166. China Tumor Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 167. China Tumor Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 168. China Tumor Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 169. Asia Tumor Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 170. Asia Tumor Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 171. Asia Tumor Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 172. Asia Tumor Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 173. Asia Tumor Treatment Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 174. Asia Tumor Treatment Drug Revenue by Region (US$ Million) & (2021-2026) Table 175. Asia Tumor Treatment Drug Revenue by Region (US$ Million) & (2027-2032) Table 176. SAMEA Tumor Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 177. SAMEA Tumor Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 178. SAMEA Tumor Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 179. SAMEA Tumor Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 180. SAMEA Tumor Treatment Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 181. SAMEA Tumor Treatment Drug Revenue by Country (2021-2026) & (US$ Million) Table 182. SAMEA Tumor Treatment Drug Revenue by Country (US$ Million) & (2027-2032) Table 183. Research Programs/Design for This Report Table 184. Authors List of This Report Table 185. Secondary Sources Table 186. Primary Sources List of Figures Figure 1. Tumor Treatment Drug Image Figure 2. Global Tumor Treatment Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tumor Treatment Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Immunotherapy (Biologic Therapy) Image Figure 5. Chemotherapy Image Figure 6. Hormonal Therapy Image Figure 7. Targeted Therapy Image Figure 8. Others Image Figure 9. Global Tumor Treatment Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Tumor Treatment Drug Market Size Share 2021 VS 2025 VS 2032 Figure 11. Respiratory/Lung Cancer Image Figure 12. Prostate Cancer Image Figure 13. Breast Cancer Image Figure 14. Gastrointestinal Cancer Image Figure 15. Blood Cancer Image Figure 16. Others Image Figure 17. Global Tumor Treatment Drug Market Size (US$ Million) & (2021-2032) Figure 18. Global Tumor Treatment Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 19. Global Tumor Treatment Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 20. Global Tumor Treatment Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Tumor Treatment Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Tumor Treatment Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Tumor Treatment Drug Revenue Market Share by Type (2021-2032) Figure 25. Global Tumor Treatment Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Tumor Treatment Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 27. Global Tumor Treatment Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Tumor Treatment Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. North America Tumor Treatment Drug Revenue Share by Type (2021-2032) Figure 30. North America Tumor Treatment Drug Revenue Share by Application (2021-2032) Figure 31. North America Tumor Treatment Drug Revenue Share by Country (2021-2032) Figure 32. United States Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Canada Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Mexico Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Europe Tumor Treatment Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 36. Europe Tumor Treatment Drug Revenue Share by Type (2021-2032) Figure 37. Europe Tumor Treatment Drug Revenue Share by Application (2021-2032) Figure 38. Europe Tumor Treatment Drug Revenue Share by Country (2021-2032) Figure 39. Germany Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. France Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. U.K. Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Italy Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Spain Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Russia Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Netherlands Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. Nordic Countries Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 47. China Tumor Treatment Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. China Tumor Treatment Drug Revenue Share by Type (2021-2032) Figure 49. China Tumor Treatment Drug Revenue Share by Application (2021-2032) Figure 50. Asia Tumor Treatment Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 51. Asia Tumor Treatment Drug Revenue Share by Type (2021-2032) Figure 52. Asia Tumor Treatment Drug Revenue Share by Application (2021-2032) Figure 53. Asia Tumor Treatment Drug Revenue Share by Region (2021-2032) Figure 54. Japan Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. South Korea Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. India Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Australia Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Taiwan Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Southeast Asia Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. SAMEA Tumor Treatment Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 61. SAMEA Tumor Treatment Drug Revenue Share by Type (2021-2032) Figure 62. SAMEA Tumor Treatment Drug Revenue Share by Application (2021-2032) Figure 63. SAMEA Tumor Treatment Drug Revenue Share by Country (2021-2032) Figure 64. Brazil Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Argentina Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Chile Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Colombia Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Peru Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Saudi Arabia Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Israel Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. UAE Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Turkey Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Iran Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Egypt Tumor Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Immunotherapy (Biologic Therapy)
  • Chemotherapy
  • Hormonal Therapy
  • Targeted Therapy
  • Others
Applications
  • Respiratory/Lung Cancer
  • Prostate Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Blood Cancer
  • Others
Companies covered
  • Astellas
  • Biogen Idec
  • Bristol-Myers Squibb
  • Celgene
  • Gilead Sciences
  • Ipsen
  • Merck & Co.
  • Otsuka
  • AstraZeneca
  • AbbVie
  • Amgen
  • Bayer
  • Pfizer
  • Eli Lilly
  • Roche
  • Merck KGaA
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Teva
  • Eisai
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Tumor Treatment Drug Market by Type
  3. 1.2.1 Global Tumor Treatment Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Immunotherapy (Biologic Therapy)
  5. 1.2.3 Chemotherapy
  6. 1.2.4 Hormonal Therapy
  7. 1.2.5 Targeted Therapy
  8. 1.2.6 Others
  9. 1.3 Tumor Treatment Drug Market by Application
  10. 1.3.1 Global Tumor Treatment Drug Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Respiratory/Lung Cancer
  12. 1.3.3 Prostate Cancer
  13. 1.3.4 Breast Cancer
  14. 1.3.5 Gastrointestinal Cancer
  15. 1.3.6 Blood Cancer
  16. 1.3.7 Others
  17. 1.4 Assumptions and Limitations
  18. 1.5 Study Goals and Objectives
2 Tumor Treatment Drug Market Dynamics
  1. 2.1 Tumor Treatment Drug Industry Trends
  2. 2.2 Tumor Treatment Drug Industry Drivers
  3. 2.3 Tumor Treatment Drug Industry Opportunities and Challenges
  4. 2.4 Tumor Treatment Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Tumor Treatment Drug Market Perspective (2021-2032)
  2. 3.2 Global Tumor Treatment Drug Growth Trends by Region
  3. 3.2.1 Global Tumor Treatment Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Tumor Treatment Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Tumor Treatment Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Tumor Treatment Drug Revenue by Players
  2. 4.1.1 Global Tumor Treatment Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Tumor Treatment Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Tumor Treatment Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Tumor Treatment Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Tumor Treatment Drug Key Players Headquarters & Area Served
  7. 4.4 Global Tumor Treatment Drug Players, Product Type & Application
  8. 4.5 Global Tumor Treatment Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Tumor Treatment Drug Market CR5 and HHI
  11. 4.6.3 2025 Tumor Treatment Drug Tier 1, Tier 2, and Tier 3
5 Tumor Treatment Drug Market Size by Type
  1. 5.1 Global Tumor Treatment Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Tumor Treatment Drug Revenue by Type (2021-2032)
  3. 5.3 Global Tumor Treatment Drug Revenue Market Share by Type (2021-2032)
6 Tumor Treatment Drug Market Size by Application
  1. 6.1 Global Tumor Treatment Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Tumor Treatment Drug Revenue by Application (2021-2032)
  3. 6.3 Global Tumor Treatment Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Astellas
  2. 7.1.1 Astellas Company Information
  3. 7.1.2 Astellas Business Overview
  4. 7.1.3 Astellas Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Astellas Tumor Treatment Drug Product Portfolio
  6. 7.1.5 Astellas Recent Developments
  7. 7.2 Biogen Idec
  8. 7.2.1 Biogen Idec Company Information
  9. 7.2.2 Biogen Idec Business Overview
  10. 7.2.3 Biogen Idec Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Biogen Idec Tumor Treatment Drug Product Portfolio
  12. 7.2.5 Biogen Idec Recent Developments
  13. 7.3 Bristol-Myers Squibb
  14. 7.3.1 Bristol-Myers Squibb Company Information
  15. 7.3.2 Bristol-Myers Squibb Business Overview
  16. 7.3.3 Bristol-Myers Squibb Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Bristol-Myers Squibb Tumor Treatment Drug Product Portfolio
  18. 7.3.5 Bristol-Myers Squibb Recent Developments
  19. 7.4 Celgene
  20. 7.4.1 Celgene Company Information
  21. 7.4.2 Celgene Business Overview
  22. 7.4.3 Celgene Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Celgene Tumor Treatment Drug Product Portfolio
  24. 7.4.5 Celgene Recent Developments
  25. 7.5 Gilead Sciences
  26. 7.5.1 Gilead Sciences Company Information
  27. 7.5.2 Gilead Sciences Business Overview
  28. 7.5.3 Gilead Sciences Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Gilead Sciences Tumor Treatment Drug Product Portfolio
  30. 7.5.5 Gilead Sciences Recent Developments
  31. 7.6 Ipsen
  32. 7.6.1 Ipsen Company Information
  33. 7.6.2 Ipsen Business Overview
  34. 7.6.3 Ipsen Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Ipsen Tumor Treatment Drug Product Portfolio
  36. 7.6.5 Ipsen Recent Developments
  37. 7.7 Merck & Co.
  38. 7.7.1 Merck & Co. Company Information
  39. 7.7.2 Merck & Co. Business Overview
  40. 7.7.3 Merck & Co. Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Merck & Co. Tumor Treatment Drug Product Portfolio
  42. 7.7.5 Merck & Co. Recent Developments
  43. 7.8 Otsuka
  44. 7.8.1 Otsuka Company Information
  45. 7.8.2 Otsuka Business Overview
  46. 7.8.3 Otsuka Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Otsuka Tumor Treatment Drug Product Portfolio
  48. 7.8.5 Otsuka Recent Developments
  49. 7.9 AstraZeneca
  50. 7.9.1 AstraZeneca Company Information
  51. 7.9.2 AstraZeneca Business Overview
  52. 7.9.3 AstraZeneca Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 AstraZeneca Tumor Treatment Drug Product Portfolio
  54. 7.9.5 AstraZeneca Recent Developments
  55. 7.10 AbbVie
  56. 7.10.1 AbbVie Company Information
  57. 7.10.2 AbbVie Business Overview
  58. 7.10.3 AbbVie Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 AbbVie Tumor Treatment Drug Product Portfolio
  60. 7.10.5 AbbVie Recent Developments
  61. 7.11 Amgen
  62. 7.11.1 Amgen Company Information
  63. 7.11.2 Amgen Business Overview
  64. 7.11.3 Amgen Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Amgen Tumor Treatment Drug Product Portfolio
  66. 7.11.5 Amgen Recent Developments
  67. 7.12 Bayer
  68. 7.12.1 Bayer Company Information
  69. 7.12.2 Bayer Business Overview
  70. 7.12.3 Bayer Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Bayer Tumor Treatment Drug Product Portfolio
  72. 7.12.5 Bayer Recent Developments
  73. 7.13 Pfizer
  74. 7.13.1 Pfizer Company Information
  75. 7.13.2 Pfizer Business Overview
  76. 7.13.3 Pfizer Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Pfizer Tumor Treatment Drug Product Portfolio
  78. 7.13.5 Pfizer Recent Developments
  79. 7.14 Eli Lilly
  80. 7.14.1 Eli Lilly Company Information
  81. 7.14.2 Eli Lilly Business Overview
  82. 7.14.3 Eli Lilly Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Eli Lilly Tumor Treatment Drug Product Portfolio
  84. 7.14.5 Eli Lilly Recent Developments
  85. 7.15 Roche
  86. 7.15.1 Roche Company Information
  87. 7.15.2 Roche Business Overview
  88. 7.15.3 Roche Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Roche Tumor Treatment Drug Product Portfolio
  90. 7.15.5 Roche Recent Developments
  91. 7.16 Merck KGaA
  92. 7.16.1 Merck KGaA Company Information
  93. 7.16.2 Merck KGaA Business Overview
  94. 7.16.3 Merck KGaA Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Merck KGaA Tumor Treatment Drug Product Portfolio
  96. 7.16.5 Merck KGaA Recent Developments
  97. 7.17 Novartis
  98. 7.17.1 Novartis Company Information
  99. 7.17.2 Novartis Business Overview
  100. 7.17.3 Novartis Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Novartis Tumor Treatment Drug Product Portfolio
  102. 7.17.5 Novartis Recent Developments
  103. 7.18 Johnson & Johnson
  104. 7.18.1 Johnson & Johnson Company Information
  105. 7.18.2 Johnson & Johnson Business Overview
  106. 7.18.3 Johnson & Johnson Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Johnson & Johnson Tumor Treatment Drug Product Portfolio
  108. 7.18.5 Johnson & Johnson Recent Developments
  109. 7.19 Sanofi
  110. 7.19.1 Sanofi Company Information
  111. 7.19.2 Sanofi Business Overview
  112. 7.19.3 Sanofi Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Sanofi Tumor Treatment Drug Product Portfolio
  114. 7.19.5 Sanofi Recent Developments
  115. 7.20 Teva
  116. 7.20.1 Teva Company Information
  117. 7.20.2 Teva Business Overview
  118. 7.20.3 Teva Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Teva Tumor Treatment Drug Product Portfolio
  120. 7.20.5 Teva Recent Developments
  121. 7.21 Eisai
  122. 7.21.1 Eisai Company Information
  123. 7.21.2 Eisai Business Overview
  124. 7.21.3 Eisai Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Eisai Tumor Treatment Drug Product Portfolio
  126. 7.21.5 Eisai Recent Developments
  127. 7.22 Takeda
  128. 7.22.1 Takeda Company Information
  129. 7.22.2 Takeda Business Overview
  130. 7.22.3 Takeda Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  131. 7.22.4 Takeda Tumor Treatment Drug Product Portfolio
  132. 7.22.5 Takeda Recent Developments
8 North America
  1. 8.1 North America Tumor Treatment Drug Revenue (2021-2032)
  2. 8.2 North America Tumor Treatment Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Tumor Treatment Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Tumor Treatment Drug Revenue by Type (2027-2032)
  5. 8.3 North America Tumor Treatment Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Tumor Treatment Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Tumor Treatment Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Tumor Treatment Drug Revenue by Application (2027-2032)
  9. 8.5 North America Tumor Treatment Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Tumor Treatment Drug Revenue by Country
  11. 8.6.1 North America Tumor Treatment Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Tumor Treatment Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Tumor Treatment Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Tumor Treatment Drug Revenue (2021-2032)
  2. 9.2 Europe Tumor Treatment Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Tumor Treatment Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Tumor Treatment Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Tumor Treatment Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Tumor Treatment Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Tumor Treatment Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Tumor Treatment Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Tumor Treatment Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Tumor Treatment Drug Revenue by Country
  11. 9.6.1 Europe Tumor Treatment Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Tumor Treatment Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Tumor Treatment Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Tumor Treatment Drug Revenue (2021-2032)
  2. 10.2 China Tumor Treatment Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Tumor Treatment Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Tumor Treatment Drug Revenue by Type (2027-2032)
  5. 10.3 China Tumor Treatment Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Tumor Treatment Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Tumor Treatment Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Tumor Treatment Drug Revenue by Application (2027-2032)
  9. 10.5 China Tumor Treatment Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Tumor Treatment Drug Revenue (2021-2032)
  2. 11.2 Asia Tumor Treatment Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Tumor Treatment Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Tumor Treatment Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Tumor Treatment Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Tumor Treatment Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Tumor Treatment Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Tumor Treatment Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Tumor Treatment Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Tumor Treatment Drug Revenue by Country
  11. 11.6.1 Asia Tumor Treatment Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Tumor Treatment Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Tumor Treatment Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Tumor Treatment Drug Revenue (2021-2032)
  2. 12.2 SAMEA Tumor Treatment Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Tumor Treatment Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Tumor Treatment Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Tumor Treatment Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Tumor Treatment Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Tumor Treatment Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Tumor Treatment Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Tumor Treatment Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Tumor Treatment Drug Revenue by Country
  11. 12.6.1 SAMEA Tumor Treatment Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Tumor Treatment Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Tumor Treatment Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst